Vanda Pharmaceuticals Inc.

• Public
• US

Dow Jones Description

We are a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, with exclusive worldwide commercial rights to two products. We believe that each of our products will address a large market with significant unmet medical needs by offering advantages over currently available therapies. Our product portfolio includes: Fanapt tm (iloperidone), a compound for the treatment of schizophrenia. On November 27, 2007, the FDA accepted a New Drug Application (NDA) for Fanapt tm for the treatment of schizophrenia. On May 6, 2009, the FDA granted U.S. marketing approval of Fanapt tm for the acute treatment of schizophrenia in adults. We expect to commercialize Fanapt tm with our own sales force and/or commercial partners in the United States and to seek partners for commercialization of the compound outside of the United States. We plan to make Fanapt tm available in pharmacies in the United States prior to the end of 2009. Holders of an NDA have 60 days after approval to file for patent term restoration under the Hatch-Waxman Act. We submitted our application for patent term restoration with respect to Fanapt tm on June 9, 2009. On July 30, 2009, we signed a Medicaid Rebate Agreement with the Secretary of Health and Human Services relating to the sale of Fanapt tm to Medicaid patients. ...

Number of Employees 24

Contact Information

Peer Companies

• Johnson & Johnson
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Novartis AG
• AstraZeneca Plc.
• All Companies